 |
News |
June 1, 2009, Somerset, NJ |
| FDA approves Novel ANDAs for GaviLyte-G (first to market generic) and GaviLyte-C, AA rated to GoLYTELY® and Colyte® respectively. GAVIS Pharmaceuticals is marketing and distributing GaviLyte-G and GaviLyte-C. |
May 27, 2009, Somerset, NJ |
| Novel receives approval from the U. S. Food and Drug Administration for its second ANDA, GaviLyte-N, therapeutic equivalent to the brand NuLytely®. Novel’s new product is being marketed and distributed by GAVIS Pharmaceuticals http://www.gavispharma.com
|
February 1, 2009, Somerset, NJ |
| Novel completes construction and opens doors to new 40,000 square foot packaging, warehousing and distribution facility. |
| |
December 8, 2008, Somerset, NJ |
| Novel receives its first ANDA approval from the Food and Drug Administration. |
| Read more >> |
|
We draw our experience and wealth of knowledge to enhance the quality life of the patient through affordable medicines.
|
|
|
|
 |
Pipeline >> |
 |
Product Development >> |
 |
Facilities >> |
 |
|
| |
Since its inception, Novel has filed 11 Abbreviated New Drug Applications with the US Food and Drug Administration.....
Read more >> |
|
Novel specializes in the development and manufacturing of orally disintegrating and modified release dosage forms.
Read more >> |
|
Novel Laboratories is centrally located in Somerset, New Jersey, 30 miles from Newark International Airport.
Read more >> |
|
| |
| |
|
|
